  Pepducins are cell-penetrating, membrane-tethered lipopeptides designed to
target the intracellular region of a G protein-coupled receptor (GPCR) in order
to allosterically modulate the receptor's signaling output. In this
proof-of-concept study, we explored the pain-relief potential of a pepducin
series derived from the first intracellular loop of neurotensin receptor type 1
(NTS1), a class A GPCR that mediates many of the effects of the neurotensin
(NT) tridecapeptide, including hypothermia, hypotension and analgesia. We used
BRET-based biosensors to determine the pepducins' ability to engage G protein
signaling pathways associated with NTS1 activation. We observed partial Gq and
G13 activation at a 10 {\mu}M concentration, indicating that these pepducins
may act as allosteric agonists of NTS1. Additionally, we used surface plasmon
resonance (SPR) as a label-free assay to monitor pepducin-induced responses in
CHO-K1 cells stably expressing hNTS1. This whole-cell integrated assay enabled
us to subdivide our pepducin series into three profile response groups. In
order to determine the pepducins' antinociceptive potential, we then screened
the series in an acute pain model (tail-flick test) by measuring tail
withdrawal latencies to a thermal nociceptive stimulus, following intrathecal
pepducin administration (275 nmol/kg). We further evaluated promising pepducins
in a tonic pain model (formalin test), as well as in neuropathic (Chronic
Constriction Injury) and inflammatory (Complete Freund's Adjuvant) chronic pain
models. We report one pepducin, PP-001, that consistently reduced rat
nociceptive behaviors, even in chronic pain paradigm. Altogether, these results
suggest that NTS1-derived pepducins may represent a promising strategy in
pain-relief.
